Aspen has a market capitalisation of approximately US$10 billion, is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks among the top 20 listed companies on this exchange.
As a leading global player in specialty, branded and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries.
Aspen operates with an established global presence in approximately 50 emerging and developed countries spanning 6 continents and employs more than 10,000 people. The Group has 26 manufacturing facilities across 18 sites. Its emerging market footprint includes Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe and the Commonwealth of Independent States, comprising Russia and the former Soviet Republics. From a developed world perspective Aspen is one of the leading pharmaceutical companies in Australia and has a growing presence in other developed countries, most notably in Western Europe.
Aspen holds international manufacturing approvals from some of the most stringent global regulatory agencies including the US FDA, TGA and EMA. Aspen’s manufacturing capabilities are scaleable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals.
Aspen’s half year gross revenue surged by 47% to R19 billion. CNBC Africa’s David Williams chatted with Aspen Group Chief Executive Stephen Saad about the results.